[Massive bleeding due to hyperfibrinolysis during living-related liver transplantation for terminal liver cirrhosis; report of two cases].
We reported two cases of massive bleeding due to critical hyperfibrinolysis during living-related liver transplantation (LRLT) for end stage liver cirrhosis. The total volume of bleeding amounted to 57930 ml with the case 1, and amounted to 55980 ml with the case 2. TEG was useful for diagnosis of the hyperfibrinolysis. We administrated large amounts of FFPs, MAPs, PLTs, and gabexate mesilate. By rapid transfusion, we could manage to finish the procedures without hypotension, and complications were not observed at the early postoperative stage. We thought that the cause of the hyperfibrinolysis is the increasing blood tissue plasminogen activator (t-PA) due to long-anhepatic stage and small graft size. During anesthesia, since the functional start of a transplant liver is indispensable to it, in order to support a transplant liver for an improvement of hyperfibrinolysis, it is important to keep the homeostasis, such as body temperature, blood pressure.
Kaku
Ryuji
R
Department of Anesthesiology and Resuscitology, School of Medicine, Okayama University, Okayama 700-8558.
Matsumi
Masaki
M
Ichiyama
Masako
M
Kajihara
Hidetoshi
H
Fujii
Hiromi
H
Ohashi
Ichirou
I
Mizobuchi
Satoshi
S
Morita
Kiyoshi
K
D000925:Anticoagulants / Q000008:administration & dosage; D016063:Blood Loss, Surgical; D001803:Blood Transfusion; D005342:Fibrinolysis; D016670:Gabexate / Q000008:administration & dosage; D006706:Homeostasis; D006801:Humans; D008103:Liver Cirrhosis / Q000601:surgery*; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013916:Thrombelastography; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D016896:Treatment Outcome
D000925:Anticoagulants; D016670:Gabexate; D010959:Tissue Plasminogen Activator